Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NeoCOAST
Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer
- NCT03794544 ↗
- Completed
- MedImmune LLC
- Deep
We haven't built an HCP commentary report on NeoCOAST (durvalumab, oleclumab and 2 more in Resectable) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NeoCOAST so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 11 | |
| YouTube | 8 | |
| Podcasts | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Subjects With Resectable, Early-stage (I [> 2 cm] to IIIA) Non-small Cell Lung Cancer (NeoCOAST)
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Resectable; Early-stage; NSCLC
- Interventions
- Durvalumab; Oleclumab; Monalizumab; Danvatirsen
- Arms
- Durvalumab 1500 mg · Experimental
- Durvalumab 1500 mg + Oleclumab 3000 mg · Experimental
- Durvalumab 1500 mg + Monalizumab 750 mg · Experimental
- Durvalumab 1500 mg + Danvatirsen 200 mg · Experimental
- Enrollment
- 84
- Primary outcomes
- Major Pathological Response Rate
- Sponsor
- MedImmune LLC
- Start
- Mar 8, 2019
- Primary completion
- Jan 13, 2021
- Results posted
- Yes
- Registry record
- NCT03794544 · updated Feb 24, 2022
Publications
linked from the registry- Cascone T, Kar G, Spicer JD, Garcia-Campelo R, Weder W, Daniel DB, Spigel DR, Hussein M, Mazieres J, Oliveira J, Yau EH, Spira AI, Anagnostou V, Mager R, Hamid O, Cheng LY, Zheng Y, Blando J, Tan TH, Surace M, Rodriguez-Canales J, Gopalakrishnan V, Sellman BR, Grenga I, Soo-Hoo Y, Kumar R, McGrath L, Forde PM. Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial. Cancer Discov. 2023 Nov 1;13(11):2394-2411. doi: 10.1158/2159-8290.CD-23-0436. PubMed 37707791